Topic:

Sales and Marketing

Latest Headlines

Latest Headlines

India warns drugmakers failure not an option for price data due next week

India's National Pharmaceutical Pricing Authority has told drugmakers that failure to hand in drug price and sales data by next week is not an option.

Branded drug prices leapt almost 15% last year, led by pain pills, COPD and heart meds

It's no secret that branded drugmakers often rely on price hikes to keep U.S. sales growth coming, especially on older meds whose patents are close to the ends of their lives. But according to new data, prices spiked more than 10% last year--a trend that may fuel the payer backlash that's been steadily mounting.

Pakistan's proposed drug-pricing policy, two years in the making, satisfies no one

SINGAPORE-- More than two years in the making, Pakistan's proposed new drug-pricing policy still hasn't won over drugmakers. The country's health ministry proffered a draft that would peg prices to those in India and Bangladesh, with generic prices at 30% less, on average, than the brand price in those neighboring countries.

Novartis braces for psoriasis pricing war as it preps for Cosentyx launch

Novartis' Cosentyx may be the first next-gen psoriasis treatment to hit the U.S. market, but it certainly won't be the last--and the Swiss drugmaker knows it. So while competitors usher their own prospects down the regulatory pathway, the company is girding for the price war it envisions in its future.

UAE forces pharma to cut prices on 280 meds as weak oil prices hit

SINGAPORE-- Beginning next month, 26 international drugmakers will be earning less in the United Arab Emirates from many of their drugs. The companies negotiated a deal with the country's Ministry of Health in the latest reduction to drug prices, with one unfortunate product's price forced down by 55%.

Emerging Asian pharma markets poised to show solid growth in 2015: report

The emerging pharmaceutical markets of Asia are expected, with a few exceptions, to grow this year and beyond, most providing attractive platforms for investments in the local industries, according to a series of analyses.

Bristol-Myers braces for Abilify patent loss, predicting big sales drop for 2015

Bristol-Myers Squibb took a top-line hit in 2014, but that's mostly because it sold its share of a diabetes alliance to partner AstraZeneca. This year, it's looking for an even bigger slide--with no big divestment to blame.

Novo Nordisk puts 500 Saxenda reps on U.S. streets, aiming for $1B in weight-loss sales

Novo Nordisk has set its Saxenda target and enlisted its U.S. sales force. Now it just needs to follow through--and that won't be an easy task.

J&J faces sales, currency headwinds abroad in 2015

Johnson & Johnson was strongly hit by weaker currencies across Asia in the fourth quarter with the company struggling to hedge risk, indicating to executives that further impacts to the bottom line in these fast-growing markets are expected in 2015.

Gilead, AbbVie rack up new payer deals, but hep C obstacles loom across the Atlantic

The hepatitis C market is breaking new ground all over the place. As payers put the squeeze on Gilead Sciences and AbbVie for discounts in the U.S., England's National Health Service is delaying a broad rollout of Gilead's blockbuster Sovaldi till July, citing the drug's high cost--an unprecedented move on a treatment already blessed by the country's cost-effectiveness watchdogs.